| 非酒精性脂肪肝对药动学影响研究进展 |
| |
| 引用本文： | 李荣辉,黄美玲,谭鸿毅,裴奇,项玉霞,阳国平. 非酒精性脂肪肝对药动学影响研究进展[J]. 金属学报, 2013, 18(9): 1065-1075 |
| |
| 作者姓名： | 李荣辉 黄美玲 谭鸿毅 裴奇 项玉霞 阳国平 |
| |
| 作者单位： | 1.中南大学药学院;2.中南大学湘雅三医院临床药理中心;3.中南大学湘雅医院耳鼻喉科;4. 中南大学湘雅三医院药剂科, 长沙 410013,湖南 |
| |
| 基金项目： | 重大疾病新药临床评价研究综合技术平台建设(2012ZX09303014-001);国家“重大新药创制”科技重大专项;POR和CYP3A4基因遗传多态性联合作用对氨氯地平降压疗效的影响及机制研究(11JJ2054);湖南省自然基金重点项目 |
| |
| 摘 要： | 非酒精性脂肪肝(NAFLD)是一种最常见的慢性肝病,严重威胁人类健康。在影响药物代谢的各种因素中,慢性肝病所起的作用最重要,可导致肝脏基因表达、mRNA及蛋白表达改变。非酒精性脂肪肝动物模型和非酒精性脂肪肝炎患者的研究结果显示,非酒精性脂肪肝时药物代谢酶及药物转运体发生显著改变。药物代谢酶和药物转运体在药物代谢过程中发挥重要作用,其改变可能影响药物在体内的清除,导致诸多临床药物的疗效、毒副作用甚至药物相互作用的发生。随着非酒精性脂肪肝的流行,越来越多的药物用于非酒精性脂肪肝患者。因此本文就非酒精性脂肪肝对药动学影响的研究进展作一综述。
|
| 关 键 词： | 非酒精性脂肪肝 药物代谢酶 药物转运体 药动学 研究进展 |
| 收稿时间： | 2012-08-30 |
| 修稿时间： | 2012-12-25 |
Advances of the influence of nonalcoholic fatty liver disease on the pharmacokinetics |
| |
| LI Rong-hui,HUANG Mei-ling,TAN Hong-yi,PEI Qi,XIANG Yu-xia,YANG Guo-ping. Advances of the influence of nonalcoholic fatty liver disease on the pharmacokinetics[J]. Acta Metallurgica Sinica, 2013, 18(9): 1065-1075 |
| |
| Authors: | LI Rong-hui HUANG Mei-ling TAN Hong-yi PEI Qi XIANG Yu-xia YANG Guo-ping |
| |
| Affiliation: | 1.Pharmaceutical College of Central South University;2.Center of Clinical Pharmacology,The Third Xiangya Hospital of Central South University;3.Department of otorhinolaryngology; Xiangya Hospital of Central South University;4.Department of Pharmacy, The Third Xiangya Hospital of Central South University,Changsha 410013, Hunan,China |
| |
| Abstract: | Nonalcoholic fatty liver disease(NAFLD) is one most common chronic liver disease,and it is a big threat against people's health.Chronic liver disease is the most important causes of effects on drug disposition,and it may lead to changes of gene,mRNA and protein expression.The results of NAFLD animal models and NAFLD patients show that drug metabolic enzymes and transporters significantly change in NAFLD. Drug metabolic enzymes and transporters play important roles in drug disposition,and lead to consequences for interindividual differences in disposition kinetics, interaction profiles of clinical drugs, susceptibility to side effects and treatment efficacy.With the prevalence of NAFLD, NAFLD patients have to take more and more drugs.So this review focuses on the influence of nonalcoholic fatty liver disease on the pharmacokinetics. |
| |
| Keywords: | Nonalcoholic fatty liver disease Drug metabolic enzyme Drug transporter Pharmacokinetics Advance |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
|
